Pharmacology and Immunotherapy Group
- Recombinant vaccines & adjuvants
- Nanotechnology & biotechnology
- Biopolymer & nanoparticle characterisation
- In vitro immunological & animal models
Department of Pharmacology and Immunotherapy is lead by Dr. Josef Mašek. The department aim is recombinant vaccines and molecular adjuvans in colaboration with Institute of Organic Chemistry and Biochemistry of AS CR; Palacky University, Olomouc; Institute of Physics AS CR); such foreign universities as Imperial College London and King´s College London) and Czech pharmaceutical companies such as Bioveta, a.s.
The result of this collaboration are publications in leading scientific journals, granted patents for new molecular adjuvants, nanoliposomal carriers for vaccine delivery, and a recombinant vaccine against borreliosis for veterinary use which is currently being developed. The Department´s researchers focus on the preparation, characterisation and application of new biocompatible nanomaterials for construction of recombinant and DNA vaccines, targeted therapeutics (antivirotics, cytostatics) and contrast agents for whole body imaging.
At the forefront of research interest is the development of systems for non-invasive vaccination (e.g. mucosal sublingual vaccination). These procedures represent one of the most recent trends in the development of safe and highly efficient vaccines for veterinary and human applications. Prominent foreign institutions have shown interest in the project dealing with the development of these systems and joint research projects have been prepared.
In collaboration with the Department of Virology, one of the novel targets is also development of pharmaceutical drugs and recombinant marker vaccines against Aujeszky’s disease, which can be transmitted from overabundant wild boar populations to hunting dogs and farm pigs.
In collaboration with the Department of Chemistry and Toxicology, testing of safety and biocompatibility of new nanomaterials is carried out under the new project of the Centre of Excellence for Nanotoxicology CENATOX. If a subsidy is granted to the Department under OP R&D&I in order to accomplish the instrumental infrastructure, a cutting-edge workplace for nanopharmacology, nanotoxicology and immunotherapy will be established at the VRI.